Curevac N.V. (CVAC)

$93.17 0.33 (0.36%)

9:32 EST CVAC Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 24,043

Day's Range 93.09 - 93.27

52-Week Range 36.15 - 151.80

Dividend & Yield N/A (N/A)

CVAC Stock Predictions, Articles, and Curevac N.V. News

From InvestorPlace
From the Web

9 New-on-Robinhood Stocks You Can Buy Now

By Josh Enomoto, InvestorPlace Contributor Oct 7, 2020

Here are the latest Robinhood stocks you can buy on the popular trading app, featuring well-rounded selections from several sectors.

CVAC Stock: CureVac Pops on Plans for Phase 2 Vaccine Trials

By Sarah Smith, InvestorPlace Web Content Producer Sep 30, 2020

CureVac just announced it was launching Phase 2 trials in Peru and Panama for its coronavirus vaccine. CVAC stock is rallying in response.

Germany Makes a $299 Million Bet on CureVac

By Will Ashworth, InvestorPlace Contributor Sep 18, 2020

CureVac recently was awarded $299 million to support the development of its Covid-19 vaccine. What does this mean for CureVac stock?

7 Coronavirus Vaccine Stocks to Watch as Approval Nears

By Thomas Niel Sep 14, 2020

Whether or not we get an 'October Surprise' from President Donald Trump, these coronavirus vaccine stocks look hot now. AstraZeneca (NYSE:AZN) CureVac (NASDAQ:CVAC) GlaxoSmithKline (NYSE:GSK) Inovio (NASDAQ:INO) Johnson & Johnson (NYSE:JNJ) Moderna (NASDAQ:MRNA) Novavax (NASDAQ:NVAX)

CureVac Stock Is Just Another Part of a Bigger Story

By Chris Markoch Sep 14, 2020

With its Covid-19 vaccine candidate, CureVac stock soared after its IPO in August. But as Operation Warp Speed wraps up, investors may wonder if there's anything else.

No Need to Rush Into CureVac Stock After Massive IPO Pop

By Matt McCall and the InvestorPlace Research Staff, Editor, MoneyWire Sep 9, 2020

CVAC stock is one of many intriguing plays on a Covid-19 vaccine. But 300% above the IPO price, investors seemingly have better options.

Why Science and Economics Might Justify CureVac

By Josh Enomoto, InvestorPlace Contributor Sep 9, 2020

Amid a sea of red ink in the Covid-19 vaccine space, CureVac stock has gone against the grain, printing some sizable gains. Can investors trust the momentum for CureVac?

Is CureVac a Buy on the Pullback? It Depends

By Thomas Niel Sep 3, 2020

Recent IPO and vaccine play CureVac stock could bounce back – but tread carefully. Much of the upside remains priced into shares.

Why CureVac Might Soar From Here

By Chris Lau, InvestorPlace Contributor Sep 2, 2020

The coronavirus vaccine play is crowded and CureVac stock needs to win more deals to get noticed

Go Easy on CureVac Stock After Its Red-Hot Market Debut

By David Moadel, InvestorPlace Contributor Sep 1, 2020

CureVac stock has been hot since its IPO thanks to its coronavirus vaccine candidate. Here's why you should give CVAC a breather now.

CureVac Stock Has Been Hot Following Its Recent IPO

By Tezcan Gecgil, InvestorPlace Contributor Sep 1, 2020

CureVac has extensive collaborations globally as well as a range of drug candidates. CureVac stock is a high-risk, high-return investment.

CureVac Stock Soars After Talks of Supplying Vaccines for the EU

By Divya Premkumar, InvestorPlace Contributor Aug 28, 2020

CureVac stock soars after the company announced that it was in talks of supplying the vaccine to EU member states.

CureVac Is a Bet on a Safe and Effective Vaccine

By Mark R. Hake, CFA Aug 26, 2020

CureVac is a bet on a winning Covid-19 vaccine that is effective and safe. Buying CureVac stock could produce a 27.5% annual compounded return over the next two years.